TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 335903
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride (intravenous administration)
Study: 25694417
Drug: Lapatinib (LAP)
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib (LAP) 1500mg monotherapy on days 1-21
Study: 20128352
Drug: Group MAP
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group MAP (antimalarial, retinol supplement, and anti-parasitic drug)
Study: 20128352
Drug: Group MA
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group MA (antimalarial and retinol supplement)
Study: 20128352
Drug: Group MP
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group MP (antimalarial and anti-parasitic drug)
Study: 20128352
Drug: Group M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group M (treatment only with antimalarials)
Study: 12723459
Drug: Intravenous dichloroacetate
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dichloroacetate (DCA) 50 mg/kg
Study: 10757193
Drug: Oxandrolone 20
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone 20 mg/day
Study: 10757193
Drug: Placebo 20
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 20 mg/day
Study: 8486815
Drug: Ethanol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (1.0 g/kg)
Study: 27462009
Drug: SMC021 (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMC021 (0.8 mg/d)
Study: 22677763
Drug: Cereton (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereton (4 ml, 1000 mg intravenously for 10 days) in combination with traditional treatment
Study: 26406216
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment only
Study: 20453679
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH), 0.075 mg x kg(‐1) x day(‐1)
Study: 17506156
Drug: Nicotine +
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine + 6 mg mecamylamine
Study: 17506156
Drug: Nicotine +
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine + 3 mg mecamylamine
Study: 6340153
Drug: Glucagon (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (1 mg I.V.)
Study: 15614570
Drug: Otovowen (alternative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otovowen (alternative treatment)
Study: 7503204
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 800 micrograms administered 3 days after methotrexate 50 mg/m2 intramuscularly (group 1)
Study: 7503204
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 800 micrograms administered 7 days after methotrexate 50 mg/m2 intramuscularly (group 2)
Study: 7503204
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to human chorionic gonadotropin-beta level < or = 25 IU/L in group 1
Study: 7503204
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to human chorionic gonadotropin-beta level < or = 25 IU/L in group 2
Study: 7503204
Drug: Treatment failures
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment failures in group 1
Study: 7503204
Drug: Treatment failure
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment failure in group 2
Study: 2188753
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g methylprednisolone (steroid) infused intravenously 2‐24 hours before planned PTCA
Study: 6792956
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (cromolyn) 40 mg
Study: 22244840
Drug: PDL +
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PDL + imiquimod 5% cream
Study: 17803845
Drug: Terazosin 2
Normalized name: terazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin 2 mg once daily for six weeks
Study: 17803845
Drug: Terazosin 2
Normalized name: terazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin 2 mg once daily and tolterodine 2 mg twice daily for six weeks
Study: 15280079
Drug: ACh (Acetylcholine)
Normalized name: By Ache
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACh (Acetylcholine) delivered via intradermal microdialysis
Study: 15280079
Drug: L-NAME (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (5 mM) delivered simultaneously via the dialysis probe
Study: 15280079
Drug: H1 receptor
Normalized name: Histamine H1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 receptor antagonist levocetirizine
Study: 24565713
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 400 μg once daily (QD) in the evening
Study: 24565713
Drug: Montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast sodium (ML) 10 mg QD pm
Study: 24565713
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 200 μg QD pm
Study: 24565713
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 250 μg twice daily
Study: 22334769
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) 400 μg
Study: 10450447
Drug: Amodiaquine (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (35 mg/kg)
Study: 10450447
Drug: Sulfadoxine-pyrimethamine (sulfadoxine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (sulfadoxine, 25 mg/kg)
Study: 2193477
Drug: Methicillin antibiotic
Normalized name: methicillin
DrugBank: Meticillin (DB01603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methicillin antibiotic prophylaxis
Study: 31961446
Drug: methyl aminolaevulinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyl aminolaevulinate photodynamic therapy (MAL-PDT)
Study: 25527482
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor physical therapy (PT)
Study: 25527482
Drug: Levator-directed trigger-point
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levator-directed trigger-point injections (LTPI)
Study: 15213034
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 16 mg.kg(‐1).d(‐1)
Study: 15213034
Drug: Methionine intakes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intakes of 3, 6, 9, 13, 18, 21, and 24 mg.kg(‐1).d(‐1)
Study: 15213034
Drug: 24‐h [(13)C]leucine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24‐h [(13)C]leucine tracer infusion
Study: 11694786
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of Herceptin (4 mg/kg initial dose followed by 2 mg/kg i.v. weekly)
Study: 11694786
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of Herceptin (8 mg/kg initial dose followed by 4 mg/kg i.v. weekly)
Study: 11694786
Drug: Herceptin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herceptin (both doses)
Study: 8065591
Drug: Dihydrogesterone with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrogesterone with transdermal estradiol
Study: 8065591
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate with transdermal estradiol
Study: 3389318
Drug: Diets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diets containing averages of 1.22‐1.67 mg/d vitamin B‐6; actual mean vitamin B‐6 content analyzed was 0.75‐0.98 mg/d.
Study: 3389318
Drug: Diets analyzed
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diets analyzed to contain means of 0.75‐0.98 mg/d of vitamin B-6.
Study: 29461420
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg) administered 15 minutes before the race and again after 5 hours if the route was not completed
Study: 29461420
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ibuprofen)
Study: 25766309
Drug: Intensive, multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive, multimodal phonologic therapy (60 hours)
Study: 20644965
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (two 30‐min classical massages per week for 5 weeks)
Study: 19929995
Drug: Taspoglutide 8
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 8 mg
Study: 19929995
Drug: Taspoglutide 30
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 30 mg
Study: 11212045
Drug: Nicorandil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (0.1 mg/kg bolus followed by infusion at 1 microg x kg(-1) x min(-1))
Study: 9877016
Drug: Sumatriptan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (100 mg PO)
Study: 3288293
Drug: Indomethacin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (single 50 mg dose)
Study: 3288293
Drug: Indomethacin (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (multiple doses of 25 and 50 mg tid for 5 days)
Study: 8383904
Drug: Propranolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (1 mg.min‐1 for 5 min followed by 0.1 mg.min‐1 for 115 min)
Study: 8383904
Drug: Propranolol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol + Isoproterenol (infused between 30 and 90 min of propranolol infusion)
Study: 2946509
Drug: Specific thromboxane
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific thromboxane synthetase inhibitor, UK-38,485
Study: 31063434
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of 120 g of cooked Moringa oleifera leaves
Study: 26576858
Drug: Betahistine 18
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 18 mg plus ondansetron 4 mg
Study: 26576858
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg alone (placebo group)
Study: 20517680
Drug: Platelet-derived growth
Normalized name: Platelet-derived growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-derived growth factors (platelet-leukocyte gel)
Study: 10918098
Drug: Prochlorperazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (10 mg intravenously)
Study: 21572992
Drug: Promethazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine (25 mg intravenously)
Study: 3886303
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tiaprofenic acid 3-times daily
Study: 24628859
Drug: Patients reporting
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients reporting monthly angina (n=188)
Study: 24628859
Drug: Patients reporting
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients reporting weekly angina (n=283)
Study: 24628859
Drug: Patients reporting
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients reporting daily angina (n=49)
Study: 15901241
Drug: Nicorandil (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (an agonist of KATP channels)
Study: 15901241
Drug: IP pretreated
Normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP pretreated with glibenclamide (an antagonist of KATP channels)
Study: 9882035
Drug: Leeds Dyspepsia
Normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leeds Dyspepsia Questionnaire (LDQ) administered to patients with dyspepsia
Study: 9882035
Drug: Leeds Dyspepsia
Normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leeds Dyspepsia Questionnaire (LDQ) before and after therapy
Study: 7927617
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (Engerix B-10 microgram each) at 0, 6 and 14 weeks (group A)
Study: 7927617
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (Engerix B-10 microgram each) at 0, 1 and 2 months (group B)
Study: 3286327
Drug: rDNA human
Normalized name: INSULIN,ULTRALENTE,HUMAN/rDNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: rDNA human insulin (HI)
Study: 20733014
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-treatment)
Study: 24228531
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine combined HAART
Study: 21642064
Drug: Robot-assisted gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted gait training (RAGT) combined with conventional physical therapy (24 1-hour sessions)
Study: 21642064
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (24 1-hour sessions)
Study: 19564366
Drug: Artemether-lumefantrine (80/480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (80/480 mg) twice daily for 3 days
Study: 19564366
Drug: Predictive modeling
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive modeling suggests a twice-daily regimen for 5 days would be preferable in later pregnancy
Study: 8280547
Drug: rectal pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rectal pethidine
Study: 6695297
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg diazoxide
Study: 6695297
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg diazoxide
Study: 6695297
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg diazoxide
Study: 30409170
Drug: Daily mobilisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mobilisation in a tilt table with an integrated stepping device (ERIGO)
Study: 26248565
Drug: Nondairy isocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondairy isocaloric and isoprotein supplement
Study: 22878686
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection (Group C)
Study: 16648324
Drug: Aripiprazole 15
Normalized name: aripiprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 15 mg/day
Study: 17663105
Drug: Electroacupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture treatment group
Study: 17663105
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-infection, inhibiting secretion of pancreas, improving microcirculation, protective agent of gastric mucosa)
Study: 11155965
Drug: TCAs plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCAs plus lithium, monoamine oxidase inhibitors (MAOIs), or electroconvulsive therapy (ECT)
Study: 8923355
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human tumor necrosis factor receptor (p80) fusion protein (rhTNFR:Fc)
Study: 28664388
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBM) from admission (AD) to D+7
Study: 28664388
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral hygiene)
Study: 23167783
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 mg daily for 14 days
Study: 23167783
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 2.0 mg daily for 14 days (Control)
Study: 14510929
Drug: Topiramate (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (50 mg daily after titration)
Study: 1326721
Drug: Thymex L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymex L (100 mg 3 times a week, total dose 1800 mg, i.m.)
Study: 3919028
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or no drug therapy (Control)
Study: 29512827
Drug: 170 μg
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 170 μg LPP administered subcutaneously over 3 weeks
Study: 24606070
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (high or low physiological dose)
Study: 11372586
Drug: Napsagatran (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Napsagatran (80 micrograms/min) + Warfarin (25 mg)
Study: 9732921
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg and amoxicillin 1 g, both given twice daily for 2 weeks (OA)
Study: 9732921
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily, clarithromycin 500 mg twice daily, and metronidazole 400 mg twice daily for 1 week (OCM)
Study: 3141099
Drug: Insulin-glyburide combination
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-glyburide combination therapy
Study: 28974203
Drug: Cefazolin administered
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin administered prior to skin incision
Study: 28974203
Drug: Cefazolin administered
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin administered after cord clamping
Study: 25846340
Drug: Faster-acting insulin
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faster-acting insulin aspart
Study: 20838775
Drug: DAMP (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAMP (20 mg/70 kg)
Study: 12439626
Drug: Placebo Nefazodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Nefazodone (0 mg/day)
Study: 10856143
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 microg combined with fluticasone 100 microg (combination product)
Study: 7974906
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus ifosfamide (VIP, VeIP) and high-dose carboplatin and etoposide with AUBMT for poor-risk GCT patients
Study: 7974906
Drug: Paclitaxel in
Normalized name: paclitaxel Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel in combination chemotherapy regimens
Study: 17643436
Drug: PHOPDT (Photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHOPDT (Photodynamic therapy with Photofrin)
Study: 11999592
Drug: Combined sciatic-femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sciatic-femoral nerve block with 25 mL mepivacaine 2% (15 mL for femoral nerve, 10 mL for sciatic nerve)
Study: 11999592
Drug: General anaesthetic
Normalized name: General anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthetic with continuous intravenous infusion of remifentanil (0.1-0.3 microgkg(‐1) min(‐1)) and propofol (target plasma concentration 2-4 microg mL(‐1))
Study: 9657355
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg p.o.)
Study: 9657355
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (i.v. infusion for 60 min at doses of 4, 8, and 16 ng/kg/min)
Study: 330302
Drug: Cholestyramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (4 g, three times daily for 3 weeks)
Study: 330302
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (dietary restriction and ad libitum antacid)
Study: 6119939
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg of morphine (postoperative)
Study: 6119939
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of pethidine (postoperative)
Study: 6119939
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg of fentanyl (postoperative)
Study: 6119939
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg of morphine (peroperative)